Protara (TARA) VP Hannah Fry granted 9,500 RSUs and 55K options

Rhea-AI Filing Summary

Protara Therapeutics VP and Controller Hannah Fry reported new equity awards. On January 16, 2026, she received 9,500 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, contingent on her continued service.

Fry was also granted a stock option for 55,000 shares of common stock with an exercise price of $5.01 per share, expiring on January 15, 2036. According to the award terms, 25% of these option shares vest on the one-year anniversary of January 16, 2026, and the remainder vest in equal monthly installments over the following three years, subject to continued service. After the RSU grant, she beneficially owned 46,312 common shares directly, and 55,000 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Fry Hannah

Role VP, Controller

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,000	$0.00	--
Grant/Award	Common Stock	9,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 55,000 shares (Direct); Common Stock — 46,312 shares (Direct)

Footnotes (1)

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fry Hannah

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Controller

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		9,500(1)	A	$0	46,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.01	01/16/2026		A		55,000		(2)	01/15/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

2. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

	/s/ Hannah Fry	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protara Therapeutics (TARA) report for Hannah Fry?

The filing shows that Hannah Fry, Protara Therapeutics' VP and Controller, received 9,500 restricted stock units of common stock and a stock option for 55,000 shares on January 16, 2026.

How many Protara Therapeutics (TARA) shares did Hannah Fry own after the reported RSU grant?

After the reported restricted stock unit grant, Hannah Fry beneficially owned 46,312 shares of Protara Therapeutics common stock, held directly.

What are the vesting terms of Hannah Fry’s 9,500 RSUs at Protara Therapeutics (TARA)?

The 9,500 RSUs vest in three equal one-third installments on the first, second, and third anniversaries of January 16, 2026, if she continues to serve the company on each vesting date.

What are the key terms of Hannah Fry’s 55,000 stock options at Protara Therapeutics (TARA)?

The stock option covers 55,000 shares of common stock with an exercise price of $5.01 per share and an expiration date of January 15, 2036. 25% of the shares vest one year after January 16, 2026, and the rest vest in monthly installments over the next three years, subject to continued service.

Is Hannah Fry’s Protara Therapeutics (TARA) equity award a direct holding?

Yes. The Form 4 identifies the 9,500 RSUs/common shares and the 55,000 stock options as held under direct (D) ownership, with no indirect ownership entity noted.

What role does Hannah Fry hold at Protara Therapeutics (TARA)?

Hannah Fry is listed as an officer of Protara Therapeutics, serving as VP, Controller, and she is required to report her equity transactions on Form 4.